AVROBIO - UHN's Gene Therapy Start-up Announces Positive Phase 1 and 2 Clinical Data

AVROBIO Inc, a UHN gene therapy start-up company, that recently IPO'ed on the NASDAQ (ticker symbol: "AVRO"), announced today that the initial clinical data for AVR-RD-01 gene therapy for AGA enzyme replacement in Fabry Disease patients were positive in both the Phase 1 and Phase II studies.

Read the full press release here: http://investors.avrobio.com/news-releases/news-release-details/avrobio-announces-updated-clinical-data-avr-rd-01-gene-therapy